Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Addition of oblimersen to docetaxel may not be beneficial in advanced prostate cancer

March 2, 2007

AT-101 monotherapy induces responses in hormone-refractory prostate cancer

March 2, 2007

New therapeutic agents for cancer covered in recent patents

March 2, 2007

Cellular and molecular targets in tumor microenvironment considered for chemoprevention

March 1, 2007

Abiraterone active in androgen-independent, castration refractory prostate cancers

March 1, 2007

DMXAA increases efficacy of docetaxel in hormone-refractory prostate cancer

March 1, 2007

Paclitaxel poliglumex active, well tolerated in androgen-independent prostate cancer

March 1, 2007

Roche and Kosan advance second-generation epothilone into phase II

March 1, 2007

BiPar Series B financing to support PARP inhibitor development

March 1, 2007

Vandetanib begins new phase III trial with pemetrexed for NSCLC

March 1, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 25, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...